Optimization and scale-up of cell culture and purification processes for production of an adenovirus-vectored tuberculosis vaccine candidate. Issue 29 (17th June 2016)

• Record Type: Journal Article
• Authors: Shen, Chun Fang; Jacob, Danielle; Zhu, Tao; Bernier, Alice; Shao, Zhongqi; Yu, Xuefeng; Patel, Mehul; Lanthier, Stephane; Kamen, Amine
• Is Part Of: Vaccine. Volume 34:Issue 29(2016)
• Page Start: 3381
• Page End: 3387
• Publication Date: 2016-06-17
• Subjects: Adenovirus-vectored vaccine -- Tuberculosis vaccine -- Cell culture -- Process development -- Purification; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2016.04.090
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: Titer of AdAg85A adenovirus was improved by more than 2 folds. Production process was successfully scaled-up to 60 L bioreactor. Over 60% recoveries of viral particles after the purification process. Purity of the purified AdAg85A was similar to ATCC Ad5 standard. The purified AdAg85A demonstrated a very good level of specific antibody responses. Abstract: Tuberculosis (TB) is the second leading cause of death by infectious disease worldwide. The only available TB vaccine is the Bacille Calmette–Guerin (BCG). However, parenterally administered Mycobacterium bovis BCG vaccine confers only limited immune protection from pulmonary tuberculosis in humans. There is a need for developing effective boosting vaccination strategies. AdAg85A, an adenoviral vector expressing the mycobacterial protein Ag85A, is a new tuberculosis vaccine candidate, and has shown promising results in pre-clinical studies and phase I trial. This adenovirus vectored vaccine is produced using HEK 293 cell culture. Here we report on the optimization of cell culture conditions, scale-up of production and purification of the AdAg85A at different scales. Four commercial serum-free media were evaluated under various conditions for supporting the growth of HEK293 cell and production of AdAg85A. A culturing strategy was employed to take advantages of two culture media with respective strengths in supporting the cell growth and virus production, which enabled to maintain virus productivity at higher cell densities and resulted in more than two folds of increases in culture titer. The production of AdAg85A was successfully scaled up and validated at 60 L bioreactor under the optimal conditions. The AdAg85A generated from the 3 L and 60 L bioreactor runs was purified through several purification steps. More than 98% of total cellular proteins was removed, over 60% of viral particles was recovered after the purification process, and purity of AdAg85A was similar to that of the ATCC VR-1516 Ad5 standard. Vaccination of mice with the purified AdAg85A demonstrated a very good level of Ag85A-specific antibody responses. The optimized production and purification conditions were transferred to a GMP facility for manufacturing of AdAg85A for generation of clinical grade material to support clinical trials.